ExploreWatchlistsPricing
  1. JP-listed companies
  2. Chiome Bioscience Inc.
  3. Financials
  4. Total current liabilities

Chiome Bioscience Inc. (4583)

Market cap
¥7B
P/E ratio
Develops antibody drugs for cancer and other diseases using its ADLib® System technology, while providing antibody development services to pharmaceutical companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal current liabilities (Million JPY)YoY (%)
Dec 31, 2025375-24.02%
Dec 31, 2024493-8.46%
Dec 31, 2023539+45.51%
Dec 31, 2022370-5.63%
Dec 31, 2021393+14.54%
Dec 31, 2020343+136.14%
Dec 31, 2019145+27.93%
Dec 31, 2018113-29.66%
Dec 31, 2017161-4.62%
Dec 31, 2016169-28.81%
Dec 31, 2015238+1.89%
Dec 31, 2014233

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat